Showing 7161-7170 of 7562 results for "".
- Two States Pass Laws Banning Indoor Tanning for Minorshttps://practicaldermatology.com/news/20140527-two_states_pass_laws_banning_indoor_tanning_for_minors/2459230/Minnesota and Louisiana have both recently passed legislation banning the use of indoor tanning facilities for those under 18 years of age. Both laws go into effect on August 1, 2014. Nine states in total have instituted bans on indoor tanning for minors, including Vermont, California, Illinois, Ore
- Clinical Trial Finds New Cream Diminishes Symptoms of Psoriasis, Eczemahttps://practicaldermatology.com/news/20140516-clinical_trial_finds_new_cream_diminishes_symptoms_of_psoriasis_eczema/2459237/Findings from an independent study indicate that the antioxidant-based Psorzema Crème formula from derma e® diminishes symptoms of eczema and psoriasis. In an eight-week study, symptomatic participants used Psorzema® Crème, all of whom showed significant improvement in dryness and flak
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- The XV World Congress on Cancers of the Skin to be Held in Edinburghhttps://practicaldermatology.com/news/20140501-the_xv_world_congress_on_cancers_of_the_skin_to_be_held_in_edinburgh/2459248/The XV World Congress on Cancers of the Skin, co-sponsored by The Skin Cancer Foundation and the British Association of Dermatologists, will be held at the Edinburgh International Conference Centre in Edinburgh, Scotland, September 3-6, 2014. The World Congress provides an opportunity for physic
- Researchers Examine UV Nail Salon Lamps and Risk of Skin Cancerhttps://practicaldermatology.com/news/20140501-researchers_examine_uv_nail_salon_lamps_and_risk_of_skin_cancer/2459249/A recent research letter in JAMA Dermatology stated that although using higher-wattage ultra violet (UV) lamps at nail salons to dry and c
- Survey Finds Rosacea Sufferers' More Likely to be Judged Negatively Upon First Impressionhttps://practicaldermatology.com/news/20140428-survey_finds__rosacea_sufferers_more_likely_to_be_judged_negatively_upon_first_impression/2459251/A new survey by the National Rosacea Society finds that rosacea sufferers' are often judged negatively upon first impression. Shy, nervous, and stressed are the three words respondents used to describe their view of an individual with redness on their face, without knowing anything about them.
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- Dermatologist Launches Kickstarter Campaignhttps://practicaldermatology.com/news/20140422-dermatologist_launches_kickstarter_campaign/2459261/Steven Feldman, MD, PhD, is spearheading a new Kickstarter campaign entitled “Changes in the Landscape” for the Coalition for Peace and Justice, an organization that welcomes all individuals and g
- Innocutis Introduces Dexter the Dystrophic Nail to Educate Patientshttps://practicaldermatology.com/news/20140417-innocutis_introduces_dexter_the_dystrophic_nail_to_educate_patients/2459265/Innocutis launched an animated social media campaign to educate on the prevalence of nail dystrophy and Nuvail as a viable treatment option. The antagonist of healthy nails in what the company calls a “fun, light-hearted, social media campaign” is